Cerebrospinal fluid HIV infection and pleocytosis: Relation to systemic infection and antiretroviral treatment

BMC Infectious Diseases

Volumn 5, Issue , 2005, Pages

  Spudich, Serena S ^a   Nilsson, Annelie C ^a   Lollo, Nicole D ^a   Liegler, Teri J ^b   Petropoulos, Christos J ^c   Deeks, Steven G ^a   Paxinos, Ellen E ^c   Price, Richard W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^c MONOGRAM BIOSCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; LAMIVUDINE; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; BLOOD SAMPLING; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMENTIA; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG RESPONSE; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY DIAGNOSIS; LEUKOCYTE COUNT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MENTAL PERFORMANCE; PLEOCYTOSIS; PROSPECTIVE STUDY; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; VIRUS DETECTION; VIRUS LOAD; BLOOD; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID; DRUG EFFECT; HIV ASSOCIATED DEMENTIA; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; LEUKOCYTOSIS; PHYSIOLOGY;

AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTOSIS; PROSPECTIVE STUDIES; RNA, VIRAL;

EID: 27844475167     PISSN: 14712334     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-5-98     Document Type: Article

References (68)

1. Navia. B, Jordan B, Price R: The AIDS dementia complex: I. Clinical Features. Ann Neurol 1986, 19:517-524.
2. Marshall D, Brey R, Cahill W, Houk R, Zajac R, Boswell R: Spectrum of cerebrospinal fluid findings in various stages of human immunodeficiency virus infection. Arch Neurol 1988, 45:954-958.
3. McArthur J, Cohen B, Farzadegan H, Cornblath D, Selnes O, Ostrow D, Johnson R, Phair J, Polk B: Cerebrospinal fluid abnormalities in homosexual men with and without neuropsychiatric findings. Ann Neurol 1988, 23(suppl):S34-S37.
4. Brew B, Pemberton L, Cunningham P, Law M: Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Inf Dis 1997, 175:963-966.
5. Pilcher CD, Shugars DC, Fiscus SA, Miller WC, Menezes P, Giner J, Dean B, Robertson K, Hart CE, Lennox JL et al: HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. Aids 2001, 15(7):837-845.
6. Ellis RJ, Hsia K, Spector SA, Nelson JA, Heaton RK, Wallace MR, Abramson I, Atkinson JH, Grant I, McCutchan JA: Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group [see comments]. Ann Neurol 1997, 42(5):679-688.
7. McArthur JC, McClernon DR, Cronin MF, Nance-Sproson TE, Saah AJ, St Clair M, Lanier ER: Relationship between human immunodefiency virus-associated dementia and viral load in cerebrospinal fluid and brain [see comments]. Ann Neurol 1997, 42(5):689-698.
8. Gisslen M, Fuchs D, Svennerholm. B, Hagberg L: Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr 1999, 21(4):271-276.
9. Price RW: The two faces of cerebrospinal fluid (CSF) HIV infection, Trends in Microbiology 2000(In press).
10. Enting R, Hoetelmans R, Lange J, Burger D, Beijnen J, Portegies P: Antiretroviral drugs and the central nervous system. AIDS 1998, 12:1941-1955.
11. Lambotte O, Deiva K, Tardieu M: HIV-1 persistence, viral reservoir, and the central nervous system in the HAART era. Brain Pathol 2003, 13(1):95-103.
12. Antinori A, Cingolani A, Giancola ML, Forbici F, De Luca A, Perno CF: Clinical implications of HIV-1 drug resistance in the neurological compartment. Scand J Infect Dis Suppl 2003, 35 Suppl 106:41-44.
13. Price RW, Staprans, S: Measuring the "viral load" in cerebrospinal fluid in human immunodeficiency virus infection: window into brain infection? [editorial; comment]. Ann Neurol 1997, 42(5):675-678.
14. Price RW, Deeks SG: Antiretroviral drag treatment interruption in human immunodeficiency virusinfected adults: Clinical and pathogenetic implications for the central nervous system. J Neurovirol 2004, 10 Suppl 1:44-51.
15. Price RW, Hoh R, Drews B, Deeks S, Grant R: Changes in cerebrospinal fluid (CSF) after interruption of antiretroviral therapy (ART): Accelerated rise in CSF HIV-1 RNA and accompanying CSF pleocytosis. In: 7th Conference on Retroviruses and Opportunistic Infections: 2000; San Francisco; 2000:306.
16. Daluge SM, Good SS, Faletto MB, Miller WH, St Clair MH, Boone LR, Tisdale M, Parry NR, Reardon JE, Dornsife RE et al: 1592U89, a novel carbocyclie nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrobial Agents and Chemotherapy 1997, 41(5):1082-1093.
17. Lanier ER, Sturge G, McClernon D, Brown S, Halman M, Sacktor N. McArthur J, Atkinson JH, Clifford D, Price RW et al: HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir. Aids 2001, 15(6):747-751.
18. Price RW, Paxinos EE, Grant RM, Drews B, Nilsson A, Hoh R, Hellmann NS, Petropoulos CJ, Deeks SG:. Cerebrospinal fluid response to structured treatment interruption after virological failure. Aids 2001, 15(10):1251-1259.
19. Price RW, Sidtis JJ: Evaluation of the AIDS dementia complex in clinical trials. J AIDS 1990, 3(Supp (2)):S51-S60.
20. Sidtis JJ: Evaluation of the AIDS dementia complex in adults. Res Publ Assoc Res Nerv Ment Dis 1994, 72:273-287.
21. Price RW: Management of AIDS dementia complex and HIV-1 infection of the nervous system. Aids 1995, 9 Suppl A:S221-236.
22. Price RW, Yiannoutsos CT, Clifford DB, Zaborski L, Tselis A, Sidtis JJ, Cohen B, Hall CD, Erice A, Henry K: Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team. Aids 1999, 13(13):1677-1685.
23. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology 1991, 41(6):778-785.
24. Sidtis JJ, Price RW: Early HIV-1 infection and the AIDS dementia complex. Neurology 1990, 40(2):323-326.
25. Staprans S, Inkina. N, Glidden D, Novakovic-Agopian T, Grant RM, Heyes M, Aweeka F, Deeks S, Price RW: Time Course of Cerebrospinal Fluid (CSF) Responses to Antiretroviral Therapy: Evidence for Variable Compartmentalization of Infection. AIDS 1999, 13:1051-1061.
26. Petroupoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ et al: A novel phenotypic drug suseptibility assay for human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy 2000, 44(4):920-928.
27. Ransohoff RM, Kivisakk P, Kidd G: Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 2003, 3(7):569-581.
28. Gisslen M, Hagberg L, Fuchs D, Norkrans G, Svennerholm B: Cerebrospinal fluid viral load in HIV-1-infected patients without antiretroviral treatment: a longitudinal study. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 17(4):291-295.
29. Stingele K, Haas J, Zimmermann T, Stingele R, Hubsch-Muller C, Freitag M, Storch-Hagenlocher B, Hartmann M, Wildemann B: Independent HIV replication in paired CSF and blood viral isolates during antiretroviral therapy. Neurology 2001, 56(3):355-361.
30. Polis MA, Suzman DL, Yoder CP, Shen JM, Mican JM, Dewar RL, Metcalf JA, Falloon J, Davey RT, Jr., Kovacs JA et al: Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen. Aids 2003, 17(8):1167-1172.
31. Ellis RJ, Childers ME, Zimmerman JD, Frost SD, Deutsch R, McCutchan JA: Human immunodeficiency virus-1 RNA levels in cerebrospinal fluid exhibit a set point in clinically stable patients not receiving antiretroviral therapy. J Infect Dis 2003, 187(11):1818-1821.
32. Martin C, Albert J, Hansson P, Pehrsson P, Link H, Sonnerborg A: Cerebrospinal fluid mononuclear cell counts influence CSF HIV-1 RNA levels. J Acquir Immun Def Syndr Human Retrovirol 1998, 17:214-219.
33. Garcia F, Niebla G, Romeu J, Vidal C, Plana M, Ortega M, Ruiz L, Gallart T, Clotet B, Miro JM et al: Cerebrospinal fluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: support for the hypothesis of local virus replication. AIDS 1999, 13(12):1491-1496.
34. Ellis RJ, Gamst AC, Capparelli E, Spector SA, Hsia K, Wolfson T, Abramson I, Grant I, McCutchan JA: Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology 2000, 54(4):927-936.
35. Eggers C, Hertogs K, Sturenburg HJ, van Lunzen J, Stellbrink HJ: Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration. Aids 2003, 17(13):1897-1906.
36. De Luca A, Ciancio BC, Larussa D, Murri R, Cingolani A, Rizzo MG, Giancola ML, Ammassari A, Ortona L: Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals. Neurology 2002, 59(3):342-347.
37. Bangsberg DR, Charlebois ED, Grant RM, Holodniy M, Deeks SG, Perry S, Conroy KN, Clark R, Guzman D, Zolopa A et al: High levels of adherence do not prevent accumulation of HIV drug resistance mutations. Aids 2003, 17(13):1925-1932.
38. Antinori A, Giancola ML, Grisetti S, Soldani F, Alba L, Liuzzi G, Amendola A, Capobianchi M, Tozzi V, Perno CF: Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1 Infected patients. Aids 2002, 16(14):1867-1876.
39. Bestetti A, Presi S, Pierotti C, Bossolasco S, Sala S, Racca S, Carrera P, Lazzarin A, Cinque P: Long-term virological effect of highly active antiretroviral therapy on cerebrospinal fluid and relationship with genotypic resistance. J Neurovirol 2004, 10 Suppl 1:52-57.
40. Siliciano JD, Siliciano RF: A long-term latent reservoir for HIV-1: discovery and clinical implications. J Antimicrob Chemother 2004, 54(1):6-9.
41. Cunningham P, Smith D, Satchell C, Cooper DA, Brew BJ: Evidence for independent development of reverse transcriptase inhibitor resistance patterns in cerebrospinal fluid. AIDS 2000.
42. Cinque P, Presi S, Bestetti A, Pierotti C, Racca S, Boeri E, Morelli P, Carrera P, Ferrari M, Lazzarin A: Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid. AIDS Res Hum Retroviruses 2001, 17(5):377-383.
43. Hickey WF, Lassmann H, Cross AH: Lymphocyte entry and the initiation of inflammation in the central nervous system. In: Immunology of the Nervous System. Edited by Keane RW, Hickey WF. New York: Oxford University Press; 1997: 200-225.
44. Strain MC, Letendre S, Pillai SK, Russell T, Ignacio CC, Gunthard HF, Good B, Smith DM, Wolinsky SM, Furtado M et al: Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretrovial therapy. J Virol 2005, 79(3):1772-1788.
45. Williams KC, Hickey WF: Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS. Annu Rev Neurosci 2002, 25:537-562.
46. Haas DW, Johnson BW, Spearman P, Raffanti S, Nicotera J, Schmidt D, Hulgan T, Shepard R, Fiscus SA: Two phases of HIV RNA decay in CSF during initial days of multidrug therapy. Neurology 2003, 61(10):1391-1396.
47. Gartner S: HIV infection and dementia. Science 2000, 287(5453):602-604.
48. Shacklett BL, Cox CA, Wilkens DT, Karl Karlsson R, Nilsson A, Nixon DF, Price RW: Increased adhesion molecule and chemokine receptor expression on CD8+ T cells trafficking to cerebrospinal fluid in HIV-1 infection. J Infect Dis 2004, 189(12):2202-2212.
49. Markowitz M, Louie M, Hurley A, Sun E, Di Mascio M, Perelson AS, Ho DD: A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol 2003, 77(8):5037-5038.
50. Morris L, Silber E, Sonnenberg P, Eintracht S, Nyoka S, Lyons S, Saffer D, Koornhof H, Martin D: High human immunodeficiency virus type 1 RNA load in the cerebrospinal fluid from patients with lymphocytic meningitis. J Infectious Diseases 1998, 177:473-476.
51. Deeks SG, Barbour JD, Grant RM, Martin JN: Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. Aids 2002, 16(2):201-207.
52. Barbour JD, Hecht FM, Wrin T, Segal MR, Ramstead CA, Liegler TJ, Busch MP, Petropoulos CJ, Hellmann NS, Kahn JO et al: Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection. J Infect Dis 2004, 190(2):251-256.
53. Foudraine N, Hoetelmans R, Lange J, deWolf F, vanBenthem B, Maas J, Keet I, Portegies P: Cerebrospinalfluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 1998, 351:1547-1551.
54. Hollander H, Stringari S: Human immunodeficiency virus-associated meningitis: Clinical course and correlations. Am J Med 1987, 83:813-816.
55. Brew BJ, Miller J: Human immunodeficiency virus-related headache. Neurology 1993, 43(6):1098-1100.
56. Hollander H, McGuire D, Burack JH: Diagnostic lumbar puncture in HIV-infected patients: analysis of 138 cases. Am J Med 1994, 96(3):223-228.
57. Krebs FC, Ross H, McAllister J, Wigdahl B: HIV-1-associated central nervous system dysfunction. Adv Pharmacol 2000, 49:315-3 85.
58. Kaul M, Garden GA, Lipton SA: Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 2001, 410(6831):988-994.
59. Turchan J, Sacktor N, Wojna V, Conant K, Nath A: Neuroprotective therapy for HIV dementia. Curr HIV Res 2003, 1(4):373-383.
60. Nath A, Berger J: HIV Dementia. Curr Treat Options Neurol 2004, 6(2):139-151.
61. Gonzalez-Scarano F, Martin-Garcia J: The neuropathogenesis of AIDS. Nat Rev Immunol 2005, 5(1):69-81.
62. McArthur JC, Hoover DR, Bacellar H, Miller EN, Cohen BA, Becker JT, Graham NM, McArthur JH, Selnes OA, Jacobson LP et al: Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 1993, 43(11):2245-2252.
63. Power C, McArthur JC, Johnson RT, Griffin DE, Glass JD, Dewey R, Chesebro B: Distinct HIV-1 env sequences are associated with neurotropism and neurovirulence. Curr Top Microbiol Immunol 1995, 202:89-104.
64. Hogan TH, Stauff DL, Krebs FC, Gartner S, Quiterio SJ, Wigdahl B: Structural and functional evolution of human immunodeficiency virus type 1 long terminal repeat CCAAT/enhancer binding protein sites and their use as molecular markers for central nervous system disease progression. J Neurovirol 2003, 9(1):55-68.
65. Power C, Zhang K, van Marle G: Comparative neurovirulence in lentiviral infections: The roles of viral molecular diversity and select proteases. J Neurovirol 2004, 10 Suppl 1:113-117.
66. Hagberg L, Fuchs D, Rosengren L, Gisslen M: Intrathecal immune activation is associated with cerebrospinal fluid markers of neuronal destruction in AIDS patients. J Neuroimmunol 2000, 102(1):51-55.
67. Abdulle S, Hagberg L, Svennerholm B, Fuchs D, Gisslen M: Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. Aids 2002, 16(16):2145-2149.
68. d'Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, Katlama C, Justesen US, Vellas S, Kirk O, Lundgren J: Changing incidence of central nervous system disease in the EuroSIDA cohort. Ann Neurol 2004, 55(3):320-328.